INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57601, 14107, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57602, 14108, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57603, 14109, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57604, 14391, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57605, 5345, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57606, 14107, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57607, 14108, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57608, 14109, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57609, 14391, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57610, 26632, 'Iodine (topical)', 'Thyroid Hormone Metabolism, Abnormal', 'Elevated serum iodine levels can lead to altered thyroid function and metabolic abnormalities in patients receiving oral iodine therapy as well as topical therapy.  Iodine should be used cautiously in patients with thyroid disorders.  Monitoring thyroid function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57611, 0, 'Iodide I-131', 'Kidney Diseases', 'Sodium iodide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57612, 0, 'Iodide I-131', 'Bone Marrow Failure Disorders', 'Sodium iodide-I-131 administered at doses used for thyroid chemotherapy induces myelosuppression including anemia, leukopenia, and thrombocytopenia.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with sodium iodide-I-131 should be administered cautiously in patients with compromised bone marrow reserve.  Clinical monitory of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57613, 12375, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57614, 12376, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57615, 29436, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57616, 29437, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57617, 29438, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57618, 12375, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57619, 12376, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57620, 29436, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57621, 29437, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57622, 29438, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57623, 12375, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57624, 12376, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57625, 29436, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57626, 29437, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57627, 29438, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57628, 12375, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57629, 12376, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57630, 29436, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57631, 29437, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57632, 29438, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57633, 12375, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57634, 12376, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57635, 29436, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57636, 29437, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57637, 29438, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57638, 12375, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57639, 12376, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57640, 29436, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57641, 29437, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57642, 29438, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57643, 12375, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57644, 12376, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57645, 29436, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57646, 29437, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57647, 29438, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57648, 0, 'Iobenguane (I-123)', 'Hypertension', 'Iobenguane I-123 may increase release of norepinephrine from chromaffin granules and produce a transient episode of hypertension.  It is recommended to assess the patient''s pulse and blood pressure before and intermittently for 30 minutes after iobenguane I-123 administration.  Care should be exercised when using this agent in patients with hypertension.  Prior to Iobenguane I-123 administration, ensure emergency cardiac and anti-hypertensive treatments are readily available.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57649, 0, 'Iobenguane (I-123)', 'Parkinson Disease', 'Individuals with conditions that affect the sympathetic nervous system, e.g., Parkinsonian syndromes such as Parkinson''s disease or multiple system atrophy, may show decreased cardiac uptake of iobenguane I-123 independent of heart disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57650, 0, 'Iobenguane (I-123)', 'Kidney Diseases', 'Iobenguane I-123 is cleared by the kidneys and is not dialyzable.  When iobenguane I-123 is used in patients with severe renal impairment, the radiation dose may be increased due to delayed elimination of the drug which may also reduce the target to background rations and decrease the quality of scintigraphic images.  Care should be exercised when using this agent in patients with severe renal impairment as the safety and efficacy have not been established in these patients.  It is recommended to consider assessment of renal function in patients prior to iobenguane I-123 administration.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57651, 3304, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57652, 3319, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57653, 11881, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57654, 11882, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57655, 0, 'Ipecac', 'Pneumonia, Aspiration', 'Ipecac induces vomiting of gastrointestinal contents that can be aspirated.  Therapy with ipecac should not be administered to patients who are less than fully conscious, severely intoxicated, in shock, having seizures, or lack gag reflexes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57656, 0, 'Ipecac', 'Cardiomyopathies', 'Ipecac may be absorbed if vomiting does not take place.  Cardiotoxicity such as tachycardia, hypotension, dyspnea, ECG changes or arrhythmia have occurred.  Chronic use to induce vomiting by patients with eating disorders has resulted in myocarditis, cardiac arrest and failure.  Therapy with ipecac should be administered cautiously in patients with or predisposition to cardiovascular dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57657, 0, 'Ipecac', 'Vascular Diseases', 'Ipecac induced vomiting can increase blood pressure.  Vomiting and retching associated with ipecac therapy may increase the risk of hemorrhage in patients with sclerotic or other pathologic changes in blood vessels.  Therapy with ipecac should be administered cautiously in patients with altered vascular physiology.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57658, 0, 'Ioxilan', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57659, 0, 'Ioxilan', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57660, 24177, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57661, 24178, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57662, 24179, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57663, 24180, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57664, 24181, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57665, 24177, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57666, 24178, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57667, 24179, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57668, 24180, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57669, 24181, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57670, 24177, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57671, 24178, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57672, 24179, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57673, 24180, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57674, 24181, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57675, 24177, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57676, 24178, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57677, 24179, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57678, 24180, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57679, 24181, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57680, 24177, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57681, 24178, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57682, 24179, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57683, 24180, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57684, 24181, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57685, 24177, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57686, 24178, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57687, 24179, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57688, 24180, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57689, 24181, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57690, 24177, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57691, 24178, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57692, 24179, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57693, 24180, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57694, 24181, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57695, 1116, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57696, 1117, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57697, 11376, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57698, 12144, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57699, 20934, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57700, 20935, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', '', 'DDInter', 0);
